

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Vanzacaftor with tezacaftor and deutivacaftor

INITIATION

Prerequisites (tick boxes where appropriate)

- ☐ Patient has been diagnosed with cystic fibrosis
- and
- ☐ Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele)
- or
- ☐ Patient has a sweat chloride value of at least 60 mmol/L
- and
- ☐ Patient has a heterozygous or homozygous F508del mutation
- or
- ☐ Patient has a mutation responsive to vanzacaftor/tezacaftor/deutivacaftor (see note)
- and
- ☐ The treatment must be the sole funded CFTR modulator therapy for this condition
- and
- ☐ Treatment with vanzacaftor/tezacaftor/deutivacaftor must be given concomitantly with standard therapy for this condition

Note: Eligible mutations are listed in the in the Food and Drug Administration (FDA) Alyftrek prescribing information https://www.accessdata.fda.gov/drugsatfda_d

I confirm that the above details are correct:

Signed: Date: